Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

WORMVACS2.0 Innovations for vaccines against helminth infections

Coordinator
Academisch Ziekenhuis Leiden, Netherlands
Runs
1 September 2023 to 31 August 2028
Status
Running
EU funding
€7.5m
Total cost
€7.5m
Partners
13 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101080784

What the project is doing

In the project's own words, from its summary on CORDIS.

Infections with parasitic worms (helminths) continue to cause a massive global health burden. Yet, effective vaccines to enable control and elimination of helminth infections do not exist. Primary reasons for this are that target discovery approaches are not well-developed, protective immune mechanisms are only partially clarified at best, production platforms tailored to specific helminth vaccine requirements are not available, and a pipeline for selecting and rapidly progressing pre-clinical and clinical vaccine candidates is generally lacking.

Moreover, controlled human infection models are only now being developed and optimized for some of the most important human helminths. These models have not yet been widely implemented in vaccine development programs to date. The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes and hookworms, and ultimately the control and elimination of some of the world’s most devastating and persistent Neglected Tropical Diseases (NTDs).

We aim to achieve this through the development and application of an innovative approach leveraging controlled human infection models, novel platforms for helminth vaccine/vaccine antigen production, experimental animal models, and improved target discovery methodology applying state-of-the-art immunological profiling to identify correlates and signatures of protection. WORMVACS2.0 will advance scientific and clinical knowledge of host immunity in response to helminth infection, apply innovative and sustainable platform technologies tailored to the next generation of effective vaccines against helminth infections of global importance.

The project will produce a diversified portfolio of hookworm and schistosome vaccine candidates ready for progressing to clinical testing and conduct a phase 1 clinical trial to advance an mRNA platform based schistosomiasis vaccine.

Topics

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis LeidenLeidenNetherlandsCoordinator
James Cook UniversityTownsvilleAustraliaAssociatedpartner
Schweizerisches Tropen Und Public Health InstitutAllschwilSwitzerlandAssociatedpartner
Linq Management GmbHBerlinGermanyParticipant
Fundacion Privada Instituto De Salud Global BarcelonaBarcelonaSpainParticipant
Centre de Recherches Medicales de LambarénéLambarénéGAParticipant
Genos Doo Za Vjestacenje I AnalizuOsijekCroatiaParticipant
Biomvis SRLSienaItalyParticipant
Wageningen UniversityWageningenNetherlandsParticipant
Uganda National Health Research OrganisationEntebbeUGParticipant
Aberystwyth UniversityAberystwythUnited KingdomAssociatedpartner
Moderna TX, IncCambridgeUnited StatesAssociatedpartner
Texas Tech University SystemLubbockUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI